Histogen
Update: Histogen Ends HST-001 (6/3/21) Histogen has announced that it is suspending the development of HST-001 aka HSC. Their latest press release appears to mark the end of the 12 year run that the “hair stimulating complex” had in this industry. Although the diplomatic word “suspending” was used, we can be all but sure this…
Read More
Update (6/22/20) The Manager of Recruitment at the California Dermatology & Clinical Research Institute reached out to me over the weekend to let me know that their site is still seeking participants for the HST-001 trial. Recruitment for the trial is scheduled to close in about 3 weeks so if you live in the San…
Read More
Histogen Doses First Patient In 1B/2A Trial – Update 6/2/20 Histogen has wasted no time in getting their latest trial of HST-001 (HSC) underway. On June 1, 2020, the company sent out a press release to announce the first male patient has been dosed in their latest trial of HSC. Positive developments seem to be…
Read More
Histogen is finally becoming a publicly traded company in 2020 after latest merger deal. On January 28, 2020, Histogen and Conatus Pharmaceuticals issued a press release announcing a definitive merger agreement between the two companies. Like Histogen, Conatus Pharmaceuticals is a biotech company based in San Diego, CA. Conatus has been publicly traded on Nasdaq…
Read More
Today, Histogen CEO Richard Pascoe presented at the BIO Investor Forum in San Francisco, CA. During his BIO presentation, Richard Pascoe discussed Histogen’s current therapeutic programs including dermal fillers, cartilage repair, and of course, hair growth. Pascoe shared that the company is planning to conduct a dose-ranging study for their lead product, HSC, in the…
Read More
This article is a continuation of a previous deep dive into one of the most fascinating stories in the biotech industry. The Ziering Study We left off in the previous article with the release of data from Dr. Craig Ziering’s independent trial of HSC. This small study has literally produced the most data we’ve ever…
Read More
The biotech startup from San Diego has had quite a background story since emerging onto the hair scene back in 2009. It had occurred to me that Histogen is now officially the longest-running “in development” hair-growth company in the world. And, when you look at that beginning date closely it starts to make sense –…
Read MoreAfter initiating a rousing new trial for female hair loss last year, Histogen has been back on many people’s radar again. A video of Histogen’s recent presentation in New York City has been uploaded online and it contains some interesting items from the company. New CEO One news item coming from Histogen earlier this year…
Read MoreNew Beauty, a magazine covering the female aesthetics industry, has released a print article featuring “hair loss solutions.” The article contains quotes and information from Dr. George Cotsarelis, RiverTown Therapeutics, and Histogen. The Brotzu Lotion is also mentioned, though with information already known. Setipiprant For Females In the article, Dr. Cotsarelis shares that his lab…
Read More
More news of progress is coming from Histogen and it’s going to raise a few eyebrows. This time, founder Gail Naughton gives details about the HSC660 trial in women and a late stage trial for men in Mexico. While browsing an article featuring Histogen on the San Diego Union Tribune website, I discovered some new…
Read More